Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma Journal Article
| Authors: | Murphy, D. A.; Rini, B. I.; Escudier, B.; Motzer, R. J.; Wang, P.; Li, S.; Williams, J. A.; Tarazi, J. C.; Martini, J. F. |
| Article Title: | Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma |
| Abstract: | Aim: Immunomodulatory mechanisms contributing to angiogenic inhibition in renal tumors are not well characterized. We report associations between efficacy and tumor-associated immune cells and mRNA/miRNA expression in patients from AXIS. Materials & methods: Immunohistochemistry (n = 52) and mRNA/miRNA expression analyses (n = 72) were performed on tumor samples. Results: In axitinib-treated patients, higher CXCR4 and TLR3 expression, respectively, was associated with longer progression-free survival (hazard ratio; 95% CI: 0.3; 0.1-0.8 and 0.4; 0.2-0.9) and showed interaction with treatment (p = 0.029 and p < 0.001); lower CCR7 expression was associated with objective response (odds ratio: 0.1; 95% CI: 0.01-1.0) and longer overall survival (hazard ratio: 3.9; 95% CI: 1.4-10.3). Conclusion: CCR7, CXCR4 and TLR3 expression levels may be prognostic/predictive of clinical benefit with axitinib. Clinical trial identifier: ClinicalTrials.gov NCT00678392. © 2020 Pfizer, B Rini, B Escudier & R Motzer. |
| Keywords: | immunohistochemistry; survival; adult; controlled study; human tissue; major clinical study; overall survival; sorafenib; drug efficacy; sensitivity and specificity; cd3 antigen; tumor associated leukocyte; progression free survival; microrna; gene expression; renal cell carcinoma; biomarker; cell density; axitinib; chemokine receptor ccr7; cd68 antigen; post hoc analysis; randomized controlled trial (topic); phase 3 clinical trial (topic); chemokine receptor cxcr4; tumor response; multicenter study (topic); cancer prognosis; toll like receptor 3; human; male; female; priority journal; article; mrna expression level |
| Journal Title: | Future Oncology |
| Volume: | 16 |
| Issue: | 17 |
| ISSN: | 1479-6694 |
| Publisher: | Future Medicine |
| Date Published: | 2020-06-01 |
| Start Page: | 1199 |
| End Page: | 1210 |
| Language: | English |
| DOI: | 10.2217/fon-2020-0212 |
| PUBMED: | 32363929 |
| PROVIDER: | scopus |
| PMCID: | PMC8459336 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 July 2020 -- Source: Scopus |
